EIF5A2 has been reported to be associated with ovarian cancer, colorectal carcinoma, hepatocellular carcinoma, breast cancer, bladder cancer, non-small cell lung cancer, gastric cancer, prostate cancer, and nasopharyngeal carcinoma [8,9,14,15,16,17,18,19,20]. Here, EIF5A2 is linked to urinary bladder carcinoma.